Veracyte (VCYT) Stock Forecast & Price Target

Veracyte is supported by a durable fundamentals story built on market-leading genomic diagnostics franchises in prostate, thyroid, breast, and bladder cancer, with more than 10x revenue growth over the past ten years (2015-2025E) and a commercial model that has repeatedly converted strong clinical evidence into reimbursement, guideline inclusion, and share gains. Its financial profile is unusually strong for a diagnostics company, with 30%+ adjusted EBITDA margins, FY2025 operating cash flow of $136.3M, $439.1M of cash and zero debt as of March 31, 2026, while management raised FY26 guidance to above 26% EBITDA margins and revenue of $582M-$592M, excluding the contribution from new launches. The outlook is further reinforced by multiple high-optionality catalysts and expanding addressable markets, including TrueMRD’s June 1, 2026 launch in muscle-invasive bladder cancer, Prosigna’s June 8, 2026 U.S. launch supported by OPTIMA, Decipher’s broadened reimbursement and 2026 NCCN inclusion, and a potential ~$275M U.S. NMIBC opportunity for UroAmp across three indications, all of which leverage the same capital-efficient whole-transcriptome platform.

Veracyte is positioned as a cash-generative genomic diagnostics company with meaningful franchise breadth, but the negative outlook stems from the fact that its growth story is already facing clear maturity and competition risks: Decipher and Afirma remain only about 33% and 38% penetrated, yet continued expansion must overcome an increasingly crowded urology market with Prolaris, MDxHealth, and ArteraAI pressuring differentiation, while Prosigna still faces reimbursement and entrenched breast-cancer competition. Although FY2025 Decipher revenue rose 27% to $310.7M and blended ASP reached about $2,980 in 2025, the investment case is exposed to execution and margin pressure because whole-genome sequencing carries higher COGS, serial-MRD pricing remains unsettled, and aggressive product expansion could compress EBITDA margins even as management expects only near-guidance margin performance rather than sharp expansion. The reliance on guideline inclusion, positive evidence readouts, and reimbursement durability also makes the franchise vulnerable if adoption slows, and with Prosigna’s U.S. relaunch still a drag, the TrueMRD launch on June 1, 2026 still early, and Percepta not arriving until around 2029, the balance of risk remains tilted toward slower-than-hoped fundamental improvement despite the company’s strong evidence base.